Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Health Sci Rep ; 7(2): e1912, 2024 Feb.
Article in English | MEDLINE | ID: mdl-38361805

ABSTRACT

Background: ChatGPT is an artificial intelligence (AI) language model that has gained popularity as a virtual assistant because of its exceptional capacity to solve problems and make decisions. However, there are some ways in which technological misuse and incorrect interpretations can have potentially hazardous consequences for a user's mental health. Discussion: Because it lacks real-time fact-checking capabilities, ChatGPT may create misleading or erroneous information. Considering AI technology has the potential to influence a person's thinking, we anticipate ChatGPT's future repercussions on mental health by considering instances in which inappropriate usage may lead to mental disorders. While several studies have demonstrated how the AI model may transform mental health care and therapy, certain drawbacks, including bias and privacy violations, have also been identified. Conclusion: Educating people and organizing workshops on AI technology usage, strengthening privacy measures, and updating ethical standards are crucial initiatives to prevent misuse and resultant dire impacts on mental health. Longitudinal research on the potential of these platforms to impact a variety of mental health problems is recommended in the future.

2.
Infect Dis Rep ; 13(4): 888-901, 2021 Oct 11.
Article in English | MEDLINE | ID: mdl-34698203

ABSTRACT

In response to the raging COVID-19 pandemic, Bangladesh started its vaccine administration in early 2021; however, due to the rapid development and launch of the vaccines in the market, many people had concerns regarding the safety of these vaccines. The purpose of this study was to evaluate the side effects that were experienced by the Bangladeshi residents after receiving the first dose of the Oxford-AstraZeneca's Covishield vaccine (ChAdOx1nCoV-19). The study was conducted using both online and printed questionnaires and the data were analysed using SPSS. The results included the responses of 474 vaccine recipients from March-April 2021. Pain at the site of injection, fever, myalgia, fatigue and headache were the most commonly reported symptoms, and the overall side effects were found to be significantly more prevalent in the younger population (p ≤ 0.05). These findings were consistent with the results indicated by the clinical trial of ChAdOx1nCoV-19. Logistic regression analysis further revealed that compared to people aged 70 years or above, the incidence of reported side effects was significantly higher in people aged 18-30 years (odds ratio (OR) = 8.56), 31-40 years, (OR = 5.05), 41-50 years (OR = 4.08), 51-60 years (OR = 3.77) and 61-70 years (OR = 3.67). In addition, a significantly higher percentage of female participants suffered from post-vaccination side effects compared to males (OR = 1.51). It was concluded that the Covishield vaccine was well-tolerated among people of different age groups. Nevertheless, further long-term follow-up study with a larger sample size is warranted to establish the long-term safety of the COVID-19 vaccine.

SELECTION OF CITATIONS
SEARCH DETAIL
...